Abstract: The present invention relates to an aqueous solution comprising burlulipase which is characterized in that it contains calcium ions. In particular, it also relates to corresponding pharmaceuticals. Such pharmaceuticals are suitable for the treatment of exocrine pancreatic insufficiency. These pharmaceuticals are particularly suitable for treating patients having cystic fibrosis and in pediatrics. Another aspect of the present invention relates to container-packaged solutions and pharmaceuticals as mentioned above, which are containers produced by the blow-fill-seal method, and to methods for producing such packaged solutions and pharmaceuticals.

Abstract: The present invention relates to an orodispersible tablet characterized in that it includes burlulipase. It also relates to liquid pharmaceutical compositions that contain solutions of such orodispersible tablets in water or other beverages. It relates to drugs that contain or consist of such orodispersible tablets or solutions. In particular, it relates to such drugs that are suitable for treating digestive problems, in particular exocrine pancreatic insufficiency used to treat digestive problems. In particular, they are for the treatment of exocrine pancreatic insufficiency in cystic fibrosis patients and for treatment of exocrine pancreatic insufficiency in pediatric patients.

Abstract: The present invention relates to an aqueous solution comprising burlulipase which is characterized in that it contains calcium ions. In particular, it also relates to corresponding pharmaceuticals. Such pharmaceuticals are suitable for the treatment of exocrine pancreatic insufficiency. These pharmaceuticals are particularly suitable for treating patients having cystic fibrosis and in pediatrics. Another aspect of the present invention relates to container-packaged solutions and pharmaceuticals as mentioned above, which are containers produced by the blow-fill-seal method, and to methods for producing such packaged solutions and pharmaceuticals.

Abstract: The present invention relates to a pharmaceutical composition comprising pancreatin, which has a coating that contains a least one lipase. Preferably the at least one lipase is burlulipase. It also relates to a medicinal product comprising such a pharmaceutical composition. A method of producing such a pharmaceutical composition also forms part of the present invention.

Abstract: The present invention relates to an orodispersible tablet characterized in that it includes burlulipase. It also relates to liquid pharmaceutical compositions that contain solutions of such orodispersible tablets in water or other beverages. It relates to drugs that contain or consist of such orodispersible tablets or solutions. In particular, it relates to such drugs that are suitable for treating digestive problems, in particular exocrine pancreatic insufficiency used to treat digestive problems. In particular, they are for the treatment of exocrine pancreatic insufficiency in cystic fibrosis patients and for treatment of exocrine pancreatic insufficiency in pediatric patients.

Abstract: The present invention relates to an aqueous solution comprising burlulipase which is characterized in that it contains calcium ions. In particular, it also relates to corresponding pharmaceuticals. Such pharmaceuticals are suitable for the treatment of exocrine pancreatic insufficiency. These pharmaceuticals are particularly suitable for treating patients having cystic fibrosis and in pediatrics. Another aspect of the present invention relates to container-packaged solutions and pharmaceuticals as mentioned above, which are containers produced by the blow-fill-seal method, and to methods for producing such packaged solutions and pharmaceuticals.

Abstract: In order to provide solid, accurately dosable pharmaceutical presentations for individual dispensing from dosing devices which are, on the one hand, stable and uniformly and evenly dosable, and which, on the other hand, permit an accurate optimal individual dosage for the most different requirements by means of an accurate divisibility at will, it is proposed that the presentations constitute small spheroidal solid bodies comprising at least one active ingredient and, when needed, also pharmaceutical inactive ingredients and which have an accurate mass and active ingredient content.